SCHEMBL1867503

SCHEMBL1867503

O=C(NNC(=O)c1cccs1)Nc1cccc(Cl)c1

nearest known ligand 0.61

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
GAA P10253 6/20 0.60
ALDH1A1 P00352 5/20 0.60
MAPT P10636 8/20 0.58
MEN1 O00255 7/20 0.58
KMT2A Q03164 7/20 0.58
LMNA P02545 4/20 0.58
HTT P42858 3/20 0.58
RAB9A P51151 6/20 0.58
NPC1 O15118 5/20 0.58
SMN1; SMN2 Q16637 3/20 0.58
TDP1 Q9NUW8 2/20 0.55
NPSR1 Q6W5P4 1/20 0.55
MAPK1 P28482 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2529744 0.87 LMNA (0.69) GAAALDH1A1MAPTMEN1KMT2A
SCHEMBL1865063 0.85 RAB9A (0.75) GAAALDH1A1MAPTMEN1KMT2A
SCHEMBL1867069 0.83 RAB9A (0.73) GAAALDH1A1MAPTMEN1KMT2A
SCHEMBL1867467 0.81 MAPT (0.55) GAAALDH1A1MAPTMEN1KMT2A
SCHEMBL1859778 0.80 RAB9A (0.70) GAAALDH1A1MAPTKMT2ALMNA
SCHEMBL2523727 0.80 KCNK3 (0.69) MAPTMEN1KMT2ALMNAHTT
SCHEMBL9046177 0.79 MEN1 (0.59) ALDH1A1MAPTMEN1KMT2ALMNA
Hydrochloric Acid SCHEMBL7078864 0.78 MEN1 (0.57) ALDH1A1MAPTMEN1KMT2ALMNA
SCHEMBL4638783 0.76 MEN1 (0.73) GAAALDH1A1MAPTMEN1KMT2A
SCHEMBL1858799 0.76 RAB9A (0.75) GAAALDH1A1MAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1478364-A2 SELECTIVE ANTIBACTERIAL AGENTS 4SC AG (DE) 2004-11-24 EP claimed
US-20040063765-A1 Modulation of pathogenicity 4 SC AG (DE) 2004-04-01 US claimed
WO-2003039549-A2 SELECTIVE ANTIBACTERIAL AGENTS 4SC AG (DE) 2003-05-15 WO claimed
US-20110105597-A1 Modulation of pathogenicity QUONOVA, LLC 2011-05-05 US disclosed
US-20100280036-A1 Modulation of Pathogenicity QUONOVA, LLC 2010-11-04 US disclosed
US-20090076012-A1 Modulation of pathogenicity QUONOVA, LLC 2009-03-19 US disclosed
US-20080214635-A1 Modulation of pathogenicity QUONOVA, LLC 2008-09-04 US disclosed
US-20080194588-A1 Modulation of pathogcnicity QUONOVA, LLC 2008-08-14 US disclosed
US-20080194607-A1 Modulation of pathogenicity QUONOVA, LLC 2008-08-14 US disclosed
US-20080188536-A1 Modulation of pathogenicity QUONOVA, LLC 2008-08-07 US disclosed
US-20080188491-A1 Modulation of pathogenicity QUONOVA, LLC 2008-08-07 US disclosed
US-20080188535-A1 Modulation of pathogenicity QUONOVA, LLC 2008-08-07 US disclosed
US-20080182878-A1 Modulation of pathogenicity QUONOVA, LLC 2008-07-31 US disclosed
US-20080176938-A1 Modulation of pathogenicity QUONOVA, LLC 2008-07-24 US disclosed
US-7335779-B2 Modulation of pathogenicity QUONOVA, LLC (US) 2008-02-26 US disclosed
EP-1478364-A2 SELECTIVE ANTIBACTERIAL AGENTS 4SC AG (DE) 2004-11-24 EP disclosed
US-20040063765-A1 Modulation of pathogenicity 4 SC AG (DE) 2004-04-01 US disclosed
WO-2003039549-A2 SELECTIVE ANTIBACTERIAL AGENTS 4SC AG (DE) 2003-05-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080194588-A1 Modulation of pathogcnicity NR4A1, NR4A2, NR3C2 GAA 4075/4885ALDH1A1 1808/4885MAPT 4719/4885
US-20090076012-A1 Modulation of pathogenicity NR4A1, NR4A2, NR4A3 GAA 3227/4885ALDH1A1 3110/4885MAPT 4855/4885
US-20110105597-A1 Modulation of pathogenicity NR4A1, NR4A2, NR4A3 GAA 3234/4885ALDH1A1 3159/4885MAPT 4855/4885
US-20080214635-A1 Modulation of pathogenicity NR4A1, NR4A2, NR4A3 GAA 3234/4885ALDH1A1 3159/4885MAPT 4855/4885
US-20100280036-A1 Modulation of Pathogenicity NR4A1, NR4A2, NR4A3 GAA 3234/4885ALDH1A1 3159/4885MAPT 4855/4885
US-20080182878-A1 Modulation of pathogenicity NR4A1, NR4A2, MSR1 GAA 3223/4885ALDH1A1 3160/4885MAPT 4856/4885
US-20080188491-A1 Modulation of pathogenicity NR4A1, MSR1, NR4A2 GAA 3503/4885ALDH1A1 2806/4885MAPT 4849/4885
US-20080194607-A1 Modulation of pathogenicity NR4A1, NR4A2, NR4A3 GAA 3234/4885ALDH1A1 3159/4885MAPT 4855/4885
US-20080188535-A1 Modulation of pathogenicity NR4A1, NR4A2, NR4A3 GAA 3234/4885ALDH1A1 3159/4885MAPT 4855/4885
US-20080188536-A1 Modulation of pathogenicity NR4A1, NR4A2, NR4A3 GAA 3234/4885ALDH1A1 3159/4885MAPT 4855/4885
US-20080176938-A1 Modulation of pathogenicity NR4A1, NR4A2, NR4A3 GAA 3240/4885ALDH1A1 2904/4885MAPT 4857/4885
US-20040063765-A1 Modulation of pathogenicity NR1H4, NR4A1, MSR1 GAA 3255/4885ALDH1A1 2935/4885MAPT 4848/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.